The evaluation of EGFR signaling effects in four gastric cancer cell lines (AGS, Hs746T, LMSU and MKN1) revealed that the MKN1 cell line (responder) was sensitive to EGF and/or cetuximab treatment in all phenotypic assays (proliferation assay [6, 7], motility assay, and invasion assay), whereas the other cell lines were either completely non-responsive (Hs746T and LMSU cells, non-responders) or sensitive in certain assays (AGS cells, partial responder). Here, EGFR is linked to gastric cancer.